The pharmacology of antibiotic therapy in hidradenitis suppurativa

References

• Kurzen H, Kurokawa I, Jemec GB, et al. What causes hidradenitis suppurativa? Exp Dermatol. 2008 May;17(5):455–456.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29:619–644.
   PubMed Web of Science ®Google Scholar
• von Laffert M, Helmbold P, Wohlrab J, et al. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol. 2010;19:533–537.
   PubMed Web of Science ®Google Scholar
• Kirsten N, Petersen J, Hagenström K, et al. Epidemiology of hidradenitis suppurativa in Germany – an observational cohort study based on a multisource approach. J Eur Acad Dermatol Venereol. 2020;34:174–179.
   PubMed Web of Science ®Google Scholar
• Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59:596–601.
   PubMed Web of Science ®Google Scholar
• Vazquez BG, Alikhan A, Weaver AL, et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. J Invest Dermatol. 2013;133:97–103.
   PubMed Web of Science ®Google Scholar
• Cosmatos I, Matcho A, Weinstein R, et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;68:412–419.
   PubMed Web of Science ®Google Scholar
• Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2010;2:9–16.
   PubMedGoogle Scholar
• Fabbrocini G, Ruocco E, De Vita V, et al. Squamous cell carcinoma arising in long standing hidradenitis suppurativa: an overlooked facet of the immunocompromised district. Clin Dermatol. 2017;35:225–227.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Fabbrocini G, Marasca C, et al. Update on pathogenesis of hidradenitis suppurativa. G Ital Dermatol Venereol. 2018 Jun;153(3 Suppl 2):3–7.
   PubMed Web of Science ®Google Scholar
• van der Zee HH, Horvath B, Jemec GB, et al. The association between hidradenitis suppurativa and Crohn’s disease: in search of the missing pathogenic link. J Invest Dermatol. 2016;136:1747–1748.
   PubMed Web of Science ®Google Scholar
• Marasca C, Donnarumma M, Annunziata MC, et al. Homocysteine plasma levels in patients affected by hidradenitis suppurativa: an Italian experience. Clin Exp Dermatol. 2019 Apr;44(3):e28–e29.
   PubMed Web of Science ®Google Scholar
• Marasca C, Balato A, Annunziata MC, et al. Insulin resistance, mTOR and hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2019 Mar;33(3):e106–e107. Epub 2018 Oct 24. No abstract available.
   PubMed Web of Science ®Google Scholar
• Barrea L, Fabbrocini G, Annunziata G, et al. Role of nutrition and adherence to the mediterranean diet in the multidisciplinary approach of hidradenitis suppurativa: evaluation of nutritional status and its association with severity of disease. Nutrients. 2018 Dec 28;11(1):pii: E57.
   PubMed Web of Science ®Google Scholar
• Saunte DM, Boer J. Stratigos. Diagnostic delay in Hidradenitis Suppurativa is a global problem. Br J Dermatol. 2015 Dec;173 675(6):1546–1549.
   Web of Science ®Google Scholar
• Ofenloch RF. Health-related quality of life in hidradenitis suppurativa. Br J Dermatol. 2017;176:861–862.
   PubMed Web of Science ®Google Scholar
• Chernyshov PV, Zouboulis CC, Tomas-Aragones L, et al. Quality of life measurement in hidradenitis suppurativa: position statement of the European academy of dermatology and venereology task forces on quality of life and patient-oriented outcomes and acne, rosacea and hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2019;33:1633–1643.
   PubMed Web of Science ®Google Scholar
• Marasca C, Napolitano M, Monfrecola G, et al. Quality of life in people living with patients suffering from hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2020 Mar 2. Epub ahead of print. DOI:10.1111/jdv.16319
   Google Scholar
• Scheinfeld N. Hidradenitis suppurativa: A practical review of possible medical treatments based on over 350 hidradenitis patients. Dermatol Online J. 2013 Apr 15;19(4):1.
   PubMedGoogle Scholar
• Scuderi N, Monfrecola A, Dessy LA, et al. Medical and surgical treatment of hidradenitis suppurativa: a review. Skin Appendage Disord. 2017 May 3;2:95–110 685.
   PubMed Web of Science ®Google Scholar
• Megna M, Bettoli V, Chimenti S, et al. Hidradenitis suppurativa: guidelines of the Italian society of dermatology and venereology (SIDeMaST) for the use of anti-TNF-a agents. G Ital Dermatol Venereol. 2015 Dec;150(6):731–739.
   PubMed Web of Science ®Google Scholar
• Gulliver W, Zouboulis CC, Prens E, et al. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based 695 on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord. 2016 Sep;17(3):343–351.
   PubMed Web of Science ®Google Scholar
• Ring HC, Emtestam L. The Microbiology of hidradenitis suppurativa. Dermatol Clin. 2016;34:29–35.
   PubMed Web of Science ®Google Scholar
• Ring HC, Riis Mikkelsen P, Miller IM et al. The bacteriology of hidradenitis suppurativa: a systematic review. Exp Dermatol. 2015;24:727–731.
   PubMed Web of Science ®Google Scholar
• Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983;22:325–332.
   PubMed Web of Science ®Google Scholar
• Jemec GBE, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis. J Am Acad Dermatol. 1998 Dec;39(6):971–974.
   PubMed Web of Science ®Google Scholar
• Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin.Int. J Dermatol. 1983;22:325.
   Web of Science ®Google Scholar
• Fischer AH, Haskin A, Okoye GA. Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2017;76:309–313.e302.
   PubMed Web of Science ®Google Scholar
• Lincosamides: chemical structure, biosynthesis, mechanism of action, resistance, and applications. Author links open overlay panelJaroslavSpížekTomášRezanka
   Google Scholar
• Frew JW, Hawkes JE and Krueger JG. Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms. Ther Adv Chronic Dis. 2019 Mar 1;10:2040622319830646.
   Web of Science ®Google Scholar
• Leigh DA Antibacterial activity and pharmacokinetics of clindamycin.
   Google Scholar
• Spizek J, Novotna J, Rezanka T. Lincosamides: chemical structure, biosynthesis, mechanism of action, resistance and applications. Adv Appl Microbiol. 2004;5, 6:1, 21–154.
   Google Scholar
• Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019 Jul;81(1):76–90. Epub 2019 Mar 11.
   PubMed Web of Science ®Google Scholar
• Albrecht J, Barbaric J, Nast A. Rifampicin alone may be enough: is it time to abandon the classic oral clindamycin-rifampicin combination for hidradenitis suppurativa? Br J Dermatol. 2019 Apr;180(4):949–950. . Epub 2019 Jan 15.
   PubMed Web of Science ®Google Scholar
• Caposiena Caro RD, Cannizzaro MV, Botti E, et al. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasound observations. J Am Acad Dermatol. 2019 May;80(5):1314–1321. Epub 2018 Nov 28.
   PubMed Web of Science ®Google Scholar
• Marasca C, Masarà A, Annunziata MC, et al. Br Long-term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa: a strategy to reduce side-effects, improving patients’ compliance. J Dermatol. 2019 Apr;180(4):949. Epub 2019 Jan 1.
   Web of Science ®Google Scholar
• Svensson RJ, Aarnoutse RE, Diacon AH, et al. A population pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction for high rifampicin doses. Clin Pharmacol Ther. 2018 Apr;103(4):674–683. Epub 2017 Aug 7.
   PubMed Web of Science ®Google Scholar
• Mandell GL. The antimicrobial activity of rifampicin – emphasis on relation to phagocytes. Rev Infect Dis. 1983;5:S463–S467.27.
   PubMedGoogle Scholar
• Renneberg J, Karlsson E, Nilsson B, et al. Interactions of drugs acting against Staphylococcus aureus in vitro and in a mouse model. J Infect. 1993;26:265–277.
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42:819–850.
   PubMed Web of Science ®Google Scholar
• van der Zee HH, Boer J, Prens EP, et al. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology. 2009;219:143–147.
   PubMed Web of Science ®Google Scholar
• Join-Lambert O, Guet-Revillet H, Lécuyer H et al. editors. The micro- biology of hidradenitis suppurativa. Chicago, IL: ICAAC; 2011.
   Google Scholar
• Simmons KB, Haddad LBNanda K, et al., Drug interactions between rifamycin antibiotics and hormonal contraception: a systematic review. BJOG. 2018 Jun;125(7):804-811. doi:10.1111/1471-0528.15027
   Google Scholar
• Mendes-Bastos P, Macedo R, Duarte R. Treatment of hidradenitis suppurativa with rifampicin: have we forgotten tuberculosis? Br J Dermatol. 2017 Oct;177(4):e150–e151. . Epub 2017 Sep 27.
   PubMed Web of Science ®Google Scholar
• Sun J, Shigemi H, Tanaka Y, et al. Tetracyclines downregulate the production of LPS-included cytokines and chemokines in THP-1 cells via ERK, p38 and nuclear factor kB signaling pathways. Biochem Biophys Res. 2015;4:397–404.
   Google Scholar
• Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39:971–974.
   PubMed Web of Science ®Google Scholar
• Vural S, Gündogdu M, Akay BN, et al. Hidradenitis suppurativa: clinical characteristics and determinants of treatment efficacy. Dermatol Ther. 2019 Sep;32(5):e13003. Epub 2019 Jul 11.
   PubMed Web of Science ®Google Scholar
• Fourtillan JB, Saux M. Comportement pharmacocinetique des tetracyclines. Revue Association pourIe. Devel Pharm Hosp Sud-Ouest. 1977;2:23–39.
   Google Scholar
• Blanchard P, Rudhardt M, Fabre J. Behaviour of doxycycline in the tissues. Chemotherapy. 1975;21:8–18.
   PubMed Web of Science ®Google Scholar
• Blanchard P, Rudhardt M, Fabre J, et al. Pharmacocinetique de divers antibiotiquesdans les tissus. Schweizerische Medizinische Wochenschrift. 1977;107:589–597.
   PubMedGoogle Scholar
• Saux MC, Mosser J, Pontagnier H, et al. Influence de I’absorption du laitsur la pharmacocinetique du polyphosphate de doxycycline. Vie Medicale. 1982a;1129-1130.
   Google Scholar
• Saux MC, Mosser J, Pontagnier H, et al. Pharmacokinetics of doxycycline polyphosphate after oral multiple dosing in humans. Eur J Drug Metab Pharmacokinet. 1982b;7:123–130.
   PubMed Web of Science ®Google Scholar
• Alestig K. Studies on absorption and excretion of doxycycline with reference to renal function. OpusculaMedica, royal college of physiology, London S. 1974;33:45–50.
   Google Scholar
• Fourtillan JB, Saux M. Interet des tetracyclines de deuxieme generation.Comportementpharmacocinetique. Semaine des Hopitaux Paris. 1978;54:224–230.
   PubMedGoogle Scholar
• Althuisius HF, Jauw TH, Janbroers JM. Ein doxycycline derivaat met bijzonndereeigenschappen: doxycycline natrium metafosfaat complex. Acta Therapeutica. 1983;9:275–287.
   Google Scholar
• Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. ClinPharmacokinet. 1988 Dec;15(6):355–366. Review.
   PubMed Web of Science ®Google Scholar
• Fischer AH, Haskin A, GA O. Patterns of antimicrobial resistance in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2017;76(2):309313.e2.
   PubMed Web of Science ®Google Scholar
• Armyra K, Kouris A, Markantoni V, et al. Hidradenitis suppurativa treated with tetracycline in combination with colchicine: a prospective series of 20 patients. Int J Dermatol. 2017;56(3):346–350.
   PubMed Web of Science ®Google Scholar
• Jonas M, Cunha BA. Minocycline. Ther Drug Monit. 1982;4:137–145.
   PubMed Web of Science ®Google Scholar
• Hessam S, Sand M, Georgas D, et al. Microbial profile and antimicrobial susceptibility of bacteria found in inflammatory hidradenitis suppurativa lesions. Skin Pharmacol Physiol. 2016;29 (3) 161–167. doi:10.1159/000446812. Epub 2016 Jun 29.
   PubMed Web of Science ®Google Scholar
• Thomas C, Rodby KA, Thomas J, et al. Recalcitrant hidradenitis suppurativa: an investigation of demographics, surgical management, bacterial isolates, pharmacologic intervention, and patient-reported health outcomes. Am Surg. 2016 Apr;82(4):362–368.
   PubMed Web of Science ®Google Scholar
• Magalhães RF, Rivitti-Machado MC, Duarte GV, et al. Consensus on the treatment of hidradenitis suppurativa-Brazilian society of dermatology. An Bras Dermatol. 2019;94(2 Suppl 1):S7–19.
   PubMed Web of Science ®Google Scholar
• Hamilton R. Tarascon pocket pharmacopoeia 2015 deluxe lab-coat Edition. Vol. 105. ISBN 9781284057560 Jones & Bartlett Learning; 2015.
   Google Scholar
• Co-trimoxazole”.The American society of health-system pharmacists.Archived from the original on 2015-09-06. Retrieved Aug 1, 2015.
   Google Scholar
• Wormser GP, Keusch GT, Heel RC. Co-trimoxazole (trimethoprim-sulfamethoxazole): an updated review of its antibacterial activity and clinical efficacy”. Drugs. 1982 December;24(6):459–518.
   PubMed Web of Science ®Google Scholar
• Bactrim BDS (trimethoprim/sulfamethoxazole) dosing, indications, interactions, adverse effects, and more”.Medscape reference. WebMD. Archived from the original on 16 January 2014. Retrieved 13 Jan 2014
   Google Scholar
• Delaunay J, Villani AP, Guillem P, et al. Oral ofloxacin and clindamycin as an alternative to the classic rifampicin clindamycin in hidradenitis suppurativa: retrospective analysis of 65 patients. Br J Dermatol. 2018;178:e15–e16.
   PubMed Web of Science ®Google Scholar
• Join-Lambert O, Coignard H, Jais JP, et al. Efficacy of rifampin-moxifloxacin- metronidazole combination therapy in hidradenitis suppurativa. Dermatology. 2011;222:49–58.
   PubMed Web of Science ®Google Scholar
• Ito F, Ohno Y, Toyoshi S, et al. Pharmacokinetics of consecutive oral moxifloxacin (400 mg/day) in patients with respiratory tract infection. Ther Adv Respir Dis. 2016 Feb;10(1):34–42.
   PubMed Web of Science ®Google Scholar
• Dingsdag SA, Hunter N. Metronidazole: an update on metabolism, structure–cytotoxicity and resistance mechanisms. J Antimicrob Chemother. 2018 Feb;73(2):265–279.
   PubMed Web of Science ®Google Scholar
• Flagyl F ER (metronidazole) dosing, indications, interactions, adverse effects, and more”. Medscape Reference. WebMD. Archived from the original on 7 April 2014. Retrieved 3 Apr 2014
   Google Scholar
• Eisenstein BI, Schaechter M. DNA and chromosome mechanics. In: Schaechter M, Engleberg NC, DiRita VJ, et al., editors. Schaechter’s mechanisms of microbial disease. Hagerstown, MD: Lippincott Williams & Wilkins; 2007. p. 28. ISBN 978-0-7817-5342-5.
   Google Scholar
• Dingsdag SA, Hunter N. Metronidazole: an update on metabolism, structure–cytotoxicity and resistance mechanisms. J Antimicrob Chemother. 2018 Feb;73(2):265, 279.
   PubMed Web of Science ®Google Scholar
• CD F, NE K, Lamp KC. Metronidazole. A therapeutic review and update. Drugs. 1997 Nov;54(5):679–708. Review. PMID: 9360057.
   PubMed Web of Science ®Google Scholar
• Zouboulis FG, Bechara JL, Dickinson-Blok W, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group. C C J Eur Acad Dermatol Venereol. 2019 Jan;33(1):19–31.
   PubMed Web of Science ®Google Scholar
• Marasca C, Annunziata MC1, Napolitano M2, Fabbrocini G1. Unconventional therapies for hidradenitis suppurativa. Expert Rev Clin Pharmacol. 2018 Sep; 11(9):879–887.
   PubMed Web of Science ®Google Scholar
• Join-Lambert O, Coignard-Biehler H, Jais J-P, et al. Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort 730 of 30 consecutive patients. J Antimicrob Chemother. 2016;71(2):513–520.
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Wiebe R, Dilay L, et al. Karlowsky comparative review of the carbapenems. Drugs. 2007;67(7):1027–1052.
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. Extensive hidradenitis suppurativa (HS) Hurly stage III disease treated with intravenous (IV) linezolid and meropenem with rapid remission. Dermatol Online J. 2015 Feb 16;21(2):pii: 13030/qt42h2744m.
   Google Scholar
• Hashemian SMR, Farhadi T, Ganjparvar M. Linezolid: a review of its properties, function, and use in critical care. Drugs Devel Ther. 2018;12:1759–1767.
   PubMed Web of Science ®Google Scholar
• Sazdanovic P, Jankovic SM, Kostic M, et al. Pharmacokinetics of linezolid in critically patients. Expert Opin Drug Metab Toxicol. 2016 Jun;12(6):595–600. . Epub 2016 Apr 7. Review.
   PubMed Web of Science ®Google Scholar
• Schleibinger M, Steinbach CL, Töpper C, et al. Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients. Br J Clin Pharmacol. 2015 Sep;80(3):525–533.
   PubMed Web of Science ®Google Scholar
• Nassif A, Coignard-Biehler H, Lortholary O, et al. Complete remission of severe hidradenitis suppurativa obtained in 4 patients using wide spectrum antimicrobial treatment. Academy of Dermatology Annual Meeting, San Diego, March 16–20, 2012, poster n.5181
   Google Scholar
• Guet-Revillet H, Jais JP, Ungeheuer MN, et al. The microbiologic all and scape of anaerobic infections in hidradenitis suppurativa: a prospective meta genomic study. ClinInfecDis. 2017;65:282–291.
   Google Scholar
• Schofer H, Simonsen L. Fusidic acid in dermatology: an updated review. Eur J Dermatol. 2010;20:6–15.
   PubMed Web of Science ®Google Scholar
• Bader HS, Hamza AS. Effective modified conservative tissue preserving protocol to treat stage I axillary hidradenitis suppurativa: a prospective cohort study of 627 patients with five years follow-up. J Dermatological Treat. 2017;28(5):458–463.
   PubMed Web of Science ®Google Scholar
• Wilson DN. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat Rev Microbiol. 2014;12:35e48.
   Web of Science ®Google Scholar
• Yoshizawa S, Fourmy D, Puglisi JD. Structural origins of gentamicin antibiotic action. Embo J. 1998;17:6437e48.
   Web of Science ®Google Scholar
• Buimer MG, Ankersmit MF, Wobbes T, et al. Surgical treatment of hidradenitis suppurativa with gentamicin sulfate: a prospective randomized study. Dermatol Surg. 2008;34(2):224–227.
   PubMed Web of Science ®Google Scholar
• Lacarrubba F, Dini V, Napolitano M, et al., Italian Ultrasound Working Group. Ultrasonography in the pathway to an optimal standard of care of hidradenitis suppurativa: the Italian ultrasound working group experience. J Eur Acad Dermatol Venereol. 2019 Oct; 6(33 Suppl):10–14.
   Google Scholar
• Bettoli V, Manfredini M, Massoli L, et al. Rates of antibiotic resistance/sensitivity in bacterial cultures of hidradenitis suppurativa patients. J Eur Acad Dermatol Venereol. 2019 May;33(5):930–936.
   PubMed Web of Science ®Google Scholar
• Albrecht J, Baine PA, Ladizinski B, et al. Long-term clinical safety of clindamycin and rifampicin combination for the treatment of hidradenitis suppurativa. A critically appraised topic. Br J Dermatol. 2019;180:749–755.
   PubMed Web of Science ®Google Scholar
• Balato A, Cacciapuoti S, Di Caprio R, et al. Human microbiome: composition and role in inflammatory skin diseases. Arch Immunol Ther Exp (Warsz). 2019 Feb;67(1):1–18. Epub 2018 Oct 9.
   PubMed Web of Science ®Google Scholar
• Jemec GB, Faber M, Gutschik E, et al. The bacteriology of hidradenitis suppurativa. Dermatology. 1996;193:203–206.
   PubMed Web of Science ®Google Scholar
• Lapins J, Jarstrand C, Emtestam L. Coagulase-negative staphylococci are the most common bacteria found in cultures from the deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol. 1999;140:90–95.
   PubMed Web of Science ®Google Scholar
• Kromann CB, Deckers IE, Esmann S, et al. Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol. 2014;171:819–824.
   PubMed Web of Science ®Google Scholar
• Sartorius K, Killasli H, Oprica C, et al. Bacteriology of hidradenitis suppurativa exacerbations and deep tissue cultures obtained during carbon dioxide laser treatment. Br J Dermatol. 2012;166:879–883.
   PubMed Web of Science ®Google Scholar
• Ring HC, Thorsen J, Saunte DM et al. the follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls. JAMA Dermatol. 2017;153:897–905.
   PubMed Web of Science ®Google Scholar
• Ring HC, Bay L, Kallenbach K et al. Normal skin microbiota is altered in pre-clinical hidradenitis suppurativa. Acta Derm Venereol. 2017;97:208–213.
   PubMed Web of Science ®Google Scholar